← back to search

Mario Silva

St. Paul's Hospital · IT
Area of research
Pulmonary and Respiratory Medicine · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Radiomics and Machine Learning in Medical Imaging, Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis, and Lung Cancer Treatments and Mutations.
h-index
40
citations
6,293
works
299
NIH funding
primary concept
Medicine
email

Recent publications

AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation.
2026cited by 0position: contributordoi
Incidence and lung cancer probability of new nodules in the UK lung screening trial
European Journal of Cancer 2026cited by 0position: contributordoi
Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening
European Journal of Cancer 2025cited by 16position: middledoi
Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer
European Journal of Cancer 2025cited by 10position: middledoi
Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening.
2025cited by 9position: contributordoi
External Test of a Deep Learning Algorithm for Pulmonary Nodule Malignancy Risk Stratification Using European Screening Data
Radiology 2025cited by 7position: middledoi
Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction.
2025cited by 7position: contributordoi
Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
2025cited by 4position: contributordoi
External Test of a Deep Learning Algorithm for Pulmonary Nodule Malignancy Risk Stratification Using European Screening Data.
2025cited by 3position: contributordoi
Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer.
2025cited by 3position: contributordoi
Current evidence of low-dose CT screening benefit.
2025cited by 2position: contributordoi
The lung cancer screening marathon after baseline: evidence from incidence nodules.
2025cited by 0position: contributordoi
Supplementary Figure S3 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Materials S1 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S5 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S7 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Data from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S1 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Table S4 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
EORTC 1417 - REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
European Journal of Cancer 2025cited by 0position: contributordoi
Supplementary Table S1 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S6 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Table S2 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Table S5 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S2 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Table S3 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
Supplementary Figure S4 from Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC
2025cited by 0position: contributordoi
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study.
2024cited by 43position: contributordoi
Study rationale and design of the PEOPLHE trial.
2024cited by 1position: contributordoi
High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study
The Lancet Respiratory Medicine 2023cited by 64position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nicola Sverzellati · St. Paul's Hospital69 papers (2018–2024) · 30 papers (2019–2026) · 8 papers (2020–2024)Matthijs Oudkerk · Accelerated Ag Technologies (United States)8 papers (2023–2026)Mathias Prokop · Analysis Group (United States)6 papers (2019–2025)Colin Jacobs · Radboud University Nijmegen6 papers (2021–2025) · 6 papers (2025–2026)John K. Field · Tianjin Medical University Cancer Institute and Hospital6 papers (2025–2026)Bram van Ginneken · University Hospital and Clinics5 papers (2020–2023)Sean B. Fain · University of Iowa4 papers (2021–2025)Jan Willem C. Gratama · University of Groningen4 papers (2025–2026) · 4 papers (2020–2024)Harriet L. Lancaster · University Medical Center Groningen4 papers (2025–2026)Aldo Carnevale · University of Ferrara3 papers (2018–2021) · 3 papers (2019–2025)Erica Maffei · University of Urbino3 papers (2019–2021) · 3 papers (2021–2025)J.L. Mulshine · Brunswick (United States)3 papers (2023–2025)Helmut Prosch · Barmherzige Schwestern Krankenhaus Wien3 papers (2020–2020)Michael P.A. Davies · The University of Texas MD Anderson Cancer Center3 papers (2025–2026)